Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma

被引:0
作者
Genhao Zhang
Xianping Lv
Qiankun Yang
Hongchun Liu
机构
[1] Zhengzhou University First Affiliated Hospital,Department of Blood transfusion
[2] Zhengzhou University First Affiliated Hospital,Department of Medical Laboratory
来源
BMC Cancer | / 22卷
关键词
HM13; Prognosis; Immune checkpoint inhibitors; HCC; Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 174 条
[1]  
Shen H(2020)Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC) Int Immunopharmacol 81 106222-377
[2]  
Wang Z(2017)Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies Eur J Cancer Prev 26 368-257
[3]  
Ren S(2013)The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection Hepatology 57 249-2455
[4]  
Wang W(2013)Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort Ann Oncol 24 2449-1638
[5]  
Duan L(2015)Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies BMJ 350 g7607-457
[6]  
Zhu D(2003)Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 1625-597
[7]  
Zhang C(2022)NAFLD-driven HCC: safety and efficacy of current and emerging treatment options J Hepatol 76 446-1314
[8]  
Duan Y(2014)Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study Hepatology 60 588-339
[9]  
Bravi F(2018)Hepatocellular carcinoma Lancet 391 1301-549
[10]  
Tavani A(2015)Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons Eur J Cancer 51 327-1916